SecBot SecBot

IMNM drug pipeline

Immunome Inc. · 6 rated drugs
$17.61
−6.2% 1-day · Nov 16
Next catalyst
Apr 28, 2027
varegacestat PDUFA date · in 162 days
Typical move on FDA news
±0.1%
1-day, median of 3 events
IV rank
No data
No current options data
Rated drugs
6
1 bullish · 5 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Apr 28, 2027162d
    varegacestat
    PDUFA date · desmoid tumors

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseFiled/PDUFA
Time to marketFDA PDUFA target action date is April 28, 2027. EMA review is also underway following MAA validation in October 2026. If approved, varegacestat could launch in the US in the second half of 2027.

varegacestat Updated Nov 10

162days
Next catalyst
PDUFA date · Apr 28, 2027 · desmoid tumors
What to watch

The single most important catalyst is the FDA PDUFA decision on April 28, 2027. Approval would make varegacestat the second FDA-approved therapy for desmoid tumors and unlock a meaningful commercial opportunity, while a Complete Response Letter would severely pressure the stock given the company's pre-revenue status and reliance on this asset. Watch for EMA review progress and Q3 earnings on November 16 for pipeline updates and cash runway details.

Bull case
  • Phase 3 RINGSIDE data were exceptionally strong: varegacestat reduced the risk of progression or death by 84% vs placebo (HR=0.16, p<0.0001) and met all key secondary endpoints, setting a high bar for approval.
  • The NDA was accepted by the FDA with a PDUFA date of April 28, 2027, and the EMA validated the MAA in October 2026, indicating dual-track regulatory progress.
  • Immunome bought out all future milestone and royalty obligations to Bristol-Myers Squibb for $20M cash plus 4.43M shares, giving it full economic ownership of varegacestat with no future payment overhang.
Bear case
  • Varegacestat would enter a market with an existing approved therapy: SpringWorks Therapeutics' Ogsiveo (nirogacestat), which generated $172M in revenue in 2024 and is already established.
  • Parabilis Medicines' zolucatetide (FOG-001), a beta-catenin inhibitor with a different mechanism, is in Phase 1/2 development for desmoid tumors and has orphan drug designation, representing future competition.
  • Immunome is pre-revenue with accelerating cash burn: R&D expenses rose 41% YoY to $69.5M, and net loss widened to $85.8M in Q3 2026 from $57.5M a year earlier.
● neutral
Impact
PhasePhase 1
Time to marketIM-1021 is in Phase 1 dose-escalation; assuming successful development, potential approval would be several years away (likely 2029-2030 at the earliest).

IM-1021 Updated Nov 12

What to watch

The next catalyst for IM-1021 is the ASH 2026 conference in December 2026, where initial Phase 1 data will be presented in detail. The early 53% response rate is encouraging for a Phase 1 dose-escalation study, but the stock's larger binary event is the varegacestat PDUFA date of April 28, 2027. Watch for ASH abstract details and any expansion cohorts or dose-confirmation data that could signal registrational intent.

Bull case
  • Initial Phase 1 data showed a 53% objective response rate in heavily pretreated B-cell non-Hodgkin lymphoma patients, including complete responses, across all dose levels evaluated.
  • IM-1021 uses Immunome's proprietary TOP1 inhibitor payload (HC74), which the company says can overcome multiple mechanisms of ADC resistance, potentially differentiating it from competitors.
  • Analyst consensus is overwhelmingly bullish: 21 analysts with 6 Strong Buy and 15 Buy ratings, a mean price target of $35.20 (84.6% upside from $19.07), and only 2 Hold ratings.
Bear case
  • Phase 1 data is early and from a small, non-randomized dose-escalation cohort; response rates often shrink in larger expansion cohorts.
  • The ROR1-targeted ADC space is competitive, with Merck's zilovertamab vedotin (formerly VLS-101) and others already in development, raising the bar for differentiation.
  • Immunome's Q3 2026 loss of $0.76/share missed estimates by $0.13, and analysts cut price targets after the report, signaling near-term financial pressure.
● neutral
Impact
PhasePhase 1
Time to marketIM-1617 is in Phase 1 dose-escalation; assuming successful development, potential approval would be several years away (likely 2029-2031 at the earliest).

IM-1617 Updated Nov 12

What to watch

IM-1617 is an early Phase 1 asset with no publicly announced data readout date. The next major catalyst for Immunome overall is the varegacestat PDUFA decision on April 28, 2027. For IM-1617 specifically, watch for any initial safety/efficacy data from the Phase 1 trial, which could emerge in 2027 at a medical conference or corporate update.

Bull case
  • IM-1617 is a potential first-in-class ADC targeting an undisclosed receptor tyrosine kinase with Immunome's proprietary TOP1 inhibitor payload HC74, offering a novel mechanism in solid tumors.
  • IND clearance was received in April 2026 and first patient dosed in June 2026, showing rapid clinical execution.
  • Immunome has a strong balance sheet ($461.6M cash, runway into 2028) to fund the Phase 1 trial without near-term dilution risk.
Bear case
  • IM-1617 is a very early-stage (Phase 1) asset with no efficacy data yet; the vast majority of Phase 1 oncology ADCs fail to advance.
  • Immunome's lead asset varegacestat is the primary value driver; IM-1617 contributes negligible standalone value to the stock at this stage.
  • The target (an undisclosed receptor tyrosine kinase) is not disclosed, making it impossible to assess differentiation vs. competing ADCs.
● neutral
Impact
PhasePreclinical / IND-enabling
Time to marketNot stated

IM-1335 Updated Nov 12

What to watch

IM-1335 is a very early-stage preclinical ADC candidate at Immunome, nominated alongside IM-1617 and IM-1340 in late 2024. The company has since advanced IM-1617 and IM-1340 into IND clearance and Phase 1, but no IND filing or clinical update for IM-1335 has been announced. Watch for any mention in future quarterly updates or corporate presentations. The drug is not a meaningful driver of IMNM's valuation at this stage; the stock's thesis rests on varegacestat (PDUFA April 28, 2027) and the IM-1021 ADC program.

Bull case
  • Immunome has a strong ADC platform with proprietary HC74 topoisomerase I inhibitor payload technology, which IM-1335 likely leverages.
  • The company has successfully advanced two other ADC candidates (IM-1617, IM-1340) from nomination to IND clearance, demonstrating execution capability.
  • Immunome has a strong cash position (reportedly $582.7M as of mid-2026 per Seeking Alpha), supporting pipeline development through 2028.
Bear case
  • IM-1335 remains in preclinical/IND-enabling stage with no disclosed IND timeline, while other nominated candidates have already advanced to Phase 1.
  • The specific target antigen has not been disclosed, making it impossible to assess differentiation or competitive positioning.
  • ADC development carries high technical risk: many preclinical ADC candidates fail to translate into clinical-stage assets.
● neutral
Impact
PhaseIND cleared / Phase 1 ready
Time to marketIM-1340 has just received IND clearance and has not yet begun patient dosing. If Phase 1 proceeds successfully, a registrational path would likely require several more years of clinical development.

IM-1340 Updated Nov 12

What to watch

IM-1340 has no near-term binary catalyst; the stock is driven by varegacestat's PDUFA on April 28, 2027. Watch for Phase 1 trial initiation and any early data disclosures, but these are unlikely to move the stock significantly given the early stage. The next company-wide event is Q3 2026 earnings on November 16, 2026.

Bull case
  • IM-1340 is described as a 'potential first-in-class' ADC, which could target a novel antigen and address an unmet need in advanced solid tumors if clinical data prove favorable.
  • Immunome has a strong ADC platform with proprietary topoisomerase I inhibitor payload (HC74), also used in IM-1021 and IM-1617, creating potential pipeline synergy.
  • Analyst consensus on Immunome is overwhelmingly bullish (21 of 23 analysts at Buy/Strong Buy) with a mean price target of $35.20, implying 84.6% upside from the current $19.07.
Bear case
  • IM-1340 is a preclinical-to-Phase 1 asset with no disclosed target antigen, making it impossible to assess differentiation vs. the crowded ADC landscape.
  • The stock fell 6.5% on the IND clearance news, suggesting the market viewed the event as a non-catalyst or even a distraction from the lead varegacestat program.
  • Immunome is pre-revenue and burning cash ($85.8M net loss in Q3 2026 per the Q3 report), and early-stage pipeline additions add to R&D spend without near-term revenue prospects.
● neutral
Impact
PhasePhase 1
Time to marketAt least 5-7 years, assuming successful Phase 1, Phase 2, and Phase 3 trials. The drug is currently in Phase 1 dose-escalation with no efficacy data yet.

IM-3050 Updated Nov 12

What to watch

IM-3050 is an early Phase 1 program with no near-term binary catalyst. The next meaningful update would likely be initial safety/dosing data from the ongoing Phase 1 trial, but no timeline for that readout has been announced. Immunome's stock is primarily driven by varegacestat (PDUFA April 28, 2027) and IM-1021 (ASH 2026 data), not IM-3050.

Bull case
  • IM-3050 targets fibroblast activation protein (FAP), which is broadly expressed across many solid tumor types, giving it a potentially large addressable patient population if successfully developed.
  • As a radioligand therapy delivering lutetium-177 directly to FAP-expressing cells, IM-3050 leverages a validated modality (radioligand therapy) that has produced approved drugs like Lutathera.
  • Immunome has a strong institutional holder base (FMR LLC, BlackRock, State Street) and analyst consensus is strongly bullish (21 Buy/Strong Buy vs 2 Hold, mean price target $35.20 implying ~85% upside).
Bear case
  • IM-3050 is in very early clinical development (Phase 1 dose-escalation), with no efficacy data yet and a high probability of failure typical of Phase 1 oncology assets.
  • The FAP-targeted radioligand therapy space is competitive, with multiple companies developing similar lutetium-177 FAP inhibitors, increasing the risk that IM-3050 may not achieve a differentiated profile.
  • Immunome reported a Q3 2026 net loss of $85.78 million and has been burning cash, with the company filing an S-3ASR shelf registration in November 2026, signaling potential future dilution.

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Jul 1, 2026varegacestatNDA filed+11.4%+14.1%
Apr 1, 2026IM-1617Approval−0.1%+2.7%
Apr 1, 2026varegacestatNDA filed−0.1%+2.7%